June 2020 Volume 16, Issue 6

Volume 16, Issue 6 | June 2020
June 2020
In this Issue
Clinical Trials

Well-tolerated tumor drug
Antibody therapeutic from Compugen demonstrates no dose-limiting toxicities
Optimal OPTICs
ADVM-022 demonstrates efficacy, durability in OPTIC trial in wet AMD
More skin in the game
Libtayo shows promise for a second indication
Usher update
ProQR offers upbeat interim analysis in Phase 1/2 trial of QR-421a for Usher Syndrome
Investigating an IL-6 antibody
An update on Sanofi and Regeneron’s Kevzara trial in hospitalized COVID-19 patientsDiagnostics

A better test for COVID-19
Digital PCR solution cuts down on false negatives, may help in clinical trials
Against antibiotic resistance
Selux Diagnostics receives additional 9.6 million for rapid AST platform
Putting the ‘AI’ in diagnostics
A look at the growing trend of integrating artificial intelligence and machine learning with diagnosticsBusiness & Government Policy

Broadening its footprint in biotech
Germany’s Sartorius acquires selected assets of Danaher Life Sciences
On the cutting edge
A roundup of instrumentation, software and other tools and technology news
Q&A: The challenges of a vaccine for COVID-19
DDN takes some time to speak with Amélie Boulais, vaccine platform marketing manager at Sartorius Stedim BiotechResearch & Development

Meaningful biomarkers
Precision medicine analyses show potential for Alzheimer’s drug
AUM launches Knockdown Coronavirus
RNA could be the kryptonite to defeat COVID-19
Building a biobank
Biogen, Broad Institute and Partners HealthCare create consortium for COVID-19 efforts
Timing is everything
Suppression of immune system may be key to reducing COVID-19 severityDiscovery

Complementary cancer collaboration
Exscientia and SRI combine strengths for oncology drug discovery
Relying on RNAi
Vir and Alnylam identify RNAi development candidate targeting SARS-CoV-2
Arrakis partners with Roche
Collaboration will use RNA-targeted small-molecule discovery platform for multiple targets
Further success in malaria initiative
Optibrium and Intellegens report in-vitro validation of in-silico-generated compound
Know your enemy
Team uses knowledge of how SARS-CoV-2 infects cells to identify drugs that could combat it
Managing macrolactones
New database could aid large-molecule drug discovery and researchContract Services

A strong complement in China
Reaction Biology, PharmaCore Labs strike up collaboration agreement
Making a deal on ADCs
Trio Pharmaceuticals and Ajinomoto enter into development collaborationPreclinical

Data recommend RECCE 327
Synthetic antibiotic shows efficacy against priority antibiotic-resistant pathogen
An autoimmune option
Immutep and Batavia Biosciences reach LAG-3 immunotherapy milestone
Negative Data Prize is a positive?
Global Preclinical Data Forum says sharing negative science results is key to neuroscience progressFeature

Focus Feature on Cancer Research News
Recent happenings on the R&D front to better understand cancer and create oncology therapeuticsCommentary

Testing, testing, testing...1,2,3,4
Diagnostic testing is hotter news right now with COVID than perhaps ever before, but what does it all mean?
Guest Commentary: Accelerating the pace of pharma innovation at a molecular level
Innovation isn’t just measured in the number of approvals, and looking at NMEs might be a better gauge of the ways in which drug discovery is currently thrivingSpecial Reports

Special Report on Cancer: Anticipating antibodies
Digging deeper into repertoires means tapping into Plan B (cell)Editor's Focus

Editor’s Focus: Cancer, COVID and change
Change is the name of the game in our understanding of cancer, the effect of COVID and the future of DDN magazine

Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe